| 2024-03-07 |
复牌提示：
2024-03-06 19:50:00 停牌，复牌日期 2024-03-08 00:00:01
|
| 2024-01-29 |
股东大会：
将于2024-03-06召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger (which we refer to, as it may be amended from time to time, as the “Merger Agreement”), dated January 5, 2024, by and among Ambrx, Johnson & Johnson, a New Jersey corporation (which we refer to as “Johnson & Johnson”), and Charm Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson (which we refer to as “Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into Ambrx (which we refer to as the “Merger”), with Ambrx surviving the Merger as a wholly owned subsidiary of Johnson & Johnson (we refer to this proposal as the “Merger Proposal”);
2.To consider and vote on a proposal to adjourn the Company Stockholders’ Meeting to a later date or dates as provided in the Merger Agreement, if necessary or appropriate, including to solicit additional votes if there are insufficient votes to adopt the Merger Agreement at the time of the Company Stockholders’ Meeting (we refer to this proposal as the “Adjournment Proposal”).
|
| 2024-01-29 |
详情>>
股本变动：
变动后总股本6335.22万股
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.03美元,归母净利润-5611.7万美元,同比去年增长16.31%
|
| 2023-09-15 |
股东大会：
将于2023-10-10召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal to approve by special resolution and adopt the Agreement and Plan of Merger, dated as of September 11, 2023 (as it may be amended from time to time, the “Merger Agreement”), by and among Ambrx, New Ambrx Biopharma Inc., a Delaware corporation and newly-formed direct wholly owned subsidiary of Ambrx (“NewCo”), and Ambrx Merger Sub Inc. (“Merger Sub”), a Cayman Islands exempted company and newly-formed direct wholly owned subsidiary of NewCo, and to authorize by special resolution the plan of merger to be registered with the Registrar of Companies of the Cayman Islands in respect of the merger (the “Cayman Plan of Merger”), by and between Ambrx and Merger Sub. The Merger Agreement and the Cayman Plan of Merger provide for, among other things, the merger of Merger Sub with and into Ambrx (the “Merger”), with Ambrx surviving the Merger as a direct wholly owned subsidiary of NewCo, and in connection therewith changing its name to “Ambrx Biopharma Cayman, Inc.”, in each case on the terms of and subject to the conditions of the Merger Agreement and the Cayman Plan of Merger as more fully described elsewhere in the accompanying proxy statement/prospectus (the “Merger Proposal”). Your approval of the Merger Proposal will constitute your approval and adoption of the Merger Agreement, the Cayman Plan of Merger, the Merger and the Proposed Organizational Documents (as defined below);
2.The Advisory Organizational Documents Proposals—on a non-binding advisory basis, to consider and vote upon the following separate proposals (collectively, the “Advisory Organizational Documents Proposals”) to approve the following differences between Ambrx’s Amended and Restated Memorandum and Articles of Association (as may be amended from time to time, the “Ambrx Governing Documents”) and the proposed new certificate of incorporation (“Proposed Certificate of Incorporation”) and the proposed new bylaws (the “Proposed Bylaws” and, together with the Proposed Certificate of Incorporation, the “Proposed Organizational Documents”) of NewCo, which are being presented separately in accordance with Securities and Exchange Commission guidance to give holders of Ambrx Ordinary Shares (as defined below) (each, an “Ambrx Ordinary Shareholder”) and holders of American Depositary Shares (“ADSs”) (each, an “Ambrx ADS Holder” and together with the Ambrx Ordinary Shareholders, the “Ambrx Shareholders”) the opportunity to present their separate views on important corporate governance provisions:(a)Advisory Organizational Documents Proposal A (“Advisory Organizational Documents Proposal A”)—on a non-binding advisory basis, to authorize the difference in authorized share capital between (a) Ambrx, which consists of $105,000 divided into 1,050,000,000 shares comprising (i) 950,000,000 ordinary shares, par value $0.0001 per share (“Ambrx Ordinary Shares”), and (ii) 100,000,000 undesignated shares, par value $0.0001 per share, of such class or classes (however designated) as the board of directors of Ambrx (the “Ambrx Board”) may determine in accordance with Articles 8 and 9 of the Ambrx Governing Documents, and (b) NewCo, which consists of 251,000,000 shares of capital stock of NewCo, comprising (i) 250,000,000 shares of common stock, par value $0.0001 per share, of NewCo (“NewCo Common Stock”) and (ii) 1,000,000 shares of preferred stock, par value $0.0001 per share, of NewCo (“NewCo Preferred Stock”);
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-0.09美元,归母净利润-3312.8万美元,同比去年增长35.66%
|
| 2023-08-09 |
详情>>
业绩披露：
2022年中报每股收益-0.19美元,归母净利润-5148.9万美元,同比去年增长-77.49%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.05美元,归母净利润-1530.2万美元,同比去年增长32.43%
|
| 2023-04-28 |
股东大会：
将于2023-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the one nominee for director to serve until the 2026 annual general meeting and until his successor shall have been appointed and qualified.
2.To approve an increase in the authorized share capital from US$60,000 divided into 600,000,000 shares of US$0.0001 each to US$60,000 divided into (a) 950,000,000 ordinary shares of US$0.0001 each, and (b) 100,000,000 shares of US$0.0001 each, of such class or classes (however designated) as the Company’s board of directors (the “Board”) may determine in accordance with our memorandum and articles of association, by the creation of (i) 350,000,000 ordinary shares of US$0.0001 each and (ii) 100,000,000 shares of US$0.0001 each of such class or classes (however designated) as our Board may determine in accordance with our memorandum and articles of association.
3.To approve, confirm and ratify the selection by the Audit Committee of the Board (the “Audit Committee”) of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
4.To approve the authorization to adjourn the Annual General Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 2. Proposal 4 will only be presented at the Annual General Meeting if there are not sufficient votes for, or otherwise in connection with, the approval of Proposal 2.
5.To conduct any other business properly brought before the meeting.
|
| 2023-04-26 |
详情>>
内部人交易：
O'Connor Daniel J.等共交易2笔
|
| 2023-03-30 |
详情>>
业绩披露：
2022年年报每股收益-0.29美元,归母净利润-7799.6万美元,同比去年增长-14.57%
|
| 2022-04-26 |
详情>>
业绩披露：
2021年年报每股收益-0.48美元,归母净利润-6807.9万美元,同比去年增长-311.53%
|
| 2021-10-28 |
详情>>
业绩披露：
2021年中报每股收益-1.63美元,归母净利润-2901万美元,同比去年增长-433.76%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-28 |
详情>>
业绩披露：
2020年年报每股收益-0.14美元,归母净利润-1654.3万美元,同比去年增长17.54%
|